Status:
COMPLETED
Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases
Lead Sponsor:
Mads Peter Godtfeldt Stemmerik
Collaborating Sponsors:
Edgewise Therapeutics, Inc.
Conditions:
Becker Muscular Dystrophy
McArdle Disease
Eligibility:
All Genders
18-50 years
Brief Summary
The purpose of the study is to explore the biomarker Fast Troponins response to exercise in patients with Becker muscular dystrophy, Limb-girdle muscular dystrophy and McArdle disease
Eligibility Criteria
Inclusion
- The ability to cycle
- No concurrent medical condition that could interfere with interpretation of the results
- Molecular diagnosis of the specific condition in specified patient groups or healthy control
- No active muscle injury on the test day (caused by recent exercise, seizures, trauma, etc.)
Exclusion
- Competing conditions at risk of compromising the results of the study
- Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous exercise
- Veins that are too difficult to puncture for blood sampling, evaluated by the investigator
- Severe muscle weakness, that prevents the subject completing the exercise test, evaluated by the investigator
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04349566
Start Date
June 1 2020
End Date
December 20 2021
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuromuscular Research Unit, 3342
Copenhagen, Denmark, DK-2100